PRALUENT

Google image searchProduct monograph

Active ingredient

alirocumab, 300 MG/2 ML

DIN: 02547732

Dosage form(s): SOLUTION

Route(s) of administration: SUBCUTANEOUS

Description: SINGLE-USE PREFILLED PEN

Schedule: Prescription / Schedule D

Company: SANOFI-AVENTIS CANADA INC

Date: 16-SEP-2024

ATC:

• C10 — LIPID MODIFYING AGENTS (ATC, ATC/DDD, )
• C10A — LIPID MODIFYING AGENTS, PLAIN (ATC, ATC/DDD)
• C10AX — Other lipid modifying agents (ATC, ATC/DDD)
• C10AX14 — ALIROCUMAB (ATC/DDD)

Reference brand drug: Praluent

External Links for Praluent

Search on Google

• Praluent side effects
• Praluent dosage
• alirocumab side effects
• alirocumab dosage

Sanofi-Aventis Canada Inc

Go to Sanofi-Aventis website to see drug product details. Sometimes you can find praluent photos and/or monograph. If you are a healthcare professional, you may need to enter your license number.